New drug MCAM takes first step toward fighting opioid addiction
NCT ID NCT07602335
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial will test the safety and blood levels of an investigational drug called MCAM in 24 healthy adults. Participants will receive a single dose of MCAM or a placebo and be monitored for 8 days. The goal is to find the highest safe dose for future studies on opioid use disorder.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MCAM (an investigational drug taken by mouth)
What this could lead to
If this early safety trial succeeds, it could pave the way for a new medication to help control opioid use disorder.
What could go wrong
This is a very early Phase 1 trial with only 24 healthy participants, so it is not designed to test effectiveness. The drug may cause side effects or fail to show benefit in later studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dr. Vince Clinical Research
Overland Park, Kansas, 66212, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••